V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330007431 | 330004240 | null | null | Curative (C) | 2014-09-10 | 2014-09-10 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330010659 | MAP |
| 330007432 | 330004242 | 1.72 | 80 | Neo-adjuvant (N) | 2014-08-14 | 2015-04-03 | Rituximab | N | N | 330010672 | RITUXIMAB |
| 330007433 | 330004243 | 1.76 | 82.5 | Curative (C) | 2015-02-18 | 2015-02-18 | Carboplatin AUC 2 - 5 | N | N | 330010672 | CARBOPLATIN |
| 330007434 | 330004243 | 1.69 | null | Curative (C) | 2017-04-05 | 2017-05-20 | CARBOPLATIN | N | N | 330010672 | CARBOPLATIN |
| 330007435 | 330004244 | null | null | Curative (C) | null | 2017-09-24 | Rituximab | N | Y | 330010681 | RITUXIMAB |
| 330007436 | 330004245 | 1.79 | 66.7 | Curative (C) | 2014-10-10 | 2014-10-12 | Carboplatin AUC 6 - 10 | N | N | 330010688 | CARBOPLATIN |
| 330007437 | 330004245 | null | null | Neo-adjuvant (N) | 2017-11-25 | 2017-12-26 | CISPLATIN + FLUOROURACIL | null | null | 330010688 | CISPLATIN + FLUOROURACIL |
| 330007438 | 330004245 | 1.6 | 38.6 | Neo-adjuvant (N) | null | 2014-07-02 | CISPLATIN + FLUOROURACIL | N | N | 330010688 | CISPLATIN + FLUOROURACIL |
| 330007439 | 330008326 | 0 | 68.2 | Palliative (P) | 2015-04-10 | 2015-04-16 | CETUXIMAB | null | null | 330010712 | CETUXIMAB |
| 330007440 | 330004251 | 0 | 63.7 | Palliative (P) | 2017-09-06 | 2017-10-04 | Cetuximab 7 day (>Cycle 2) | N | N | 330010712 | CETUXIMAB |
| 330007441 | 330012409 | 1.91 | 66 | Palliative (P) | null | 2017-04-01 | Rituximab | null | N | 330010738 | RITUXIMAB |
| 330007442 | 330004252 | null | 79.2 | Palliative (P) | 2017-01-04 | 2017-01-19 | Docetaxel + Gemcitabine (prior RT) | N | N | 330010739 | DOCETAXEL + GEMCITABINE |
| 330007443 | 330008328 | 1.7 | 95.1 | Curative (C) | 2018-05-16 | 2018-05-18 | Cetuximab 7 day (>Cycle 2) | 02 | N | 330010739 | CETUXIMAB |
| 330007444 | 330004254 | 1.88 | 59.4 | Neo-adjuvant (N) | 2016-11-15 | 2016-11-21 | ETOPOSIDE + IFOSFAMIDE | N | Y | 330010747 | ETOPOSIDE + IFOSFAMIDE |
| 330007445 | 330004255 | 1.73 | null | Palliative (P) | 2017-06-17 | 2017-07-01 | OST Euramos 1 Closed Trial - M | 02 | null | 330010755 | METHOTREXATE HIGH DOSE |
| 330007446 | 330008330 | 1.66 | 63 | Palliative (P) | 2015-08-18 | 2015-08-18 | CISPLATIN + FLUOROURACIL | N | N | 330010763 | CISPLATIN + FLUOROURACIL |
| 330007447 | 330004256 | 1.61 | 65 | Neo-adjuvant (N) | 2016-09-06 | 2016-09-07 | Etoposide + Ifosfamide (3 days) | N | Y | 330010766 | ETOPOSIDE + IFOSFAMIDE |
| 330007448 | 330004256 | 1.68 | 65 | Palliative (P) | 2017-01-08 | 2017-01-08 | Docetaxel+Gemcitabine (no prior RT) | N | N | 330010766 | DOCETAXEL + GEMCITABINE |
| 330007449 | 330004257 | 1.71 | 70.6 | Palliative (P) | 2013-08-04 | 2013-08-04 | PAM | 02 | N | 330010803 | MAP |
| 330007450 | 330004259 | 1.57 | 67.5 | Curative (C) | 2015-03-03 | 2015-03-29 | OST Euramos 1 Closed Trial - M | N | N | 330010826 | METHOTREXATE HIGH DOSE |
| 330007451 | 330004259 | 1.8 | 88.4 | Curative (C) | 2016-10-11 | 2016-10-15 | OST Euramos 1 Closed Trial - M | 02 | N | 330010826 | METHOTREXATE HIGH DOSE |
| 330007452 | 330004259 | null | 66.6 | Curative (C) | 2017-06-12 | 2017-06-14 | Methotrexate High Dose (3g/m2) | N | N | 330010826 | METHOTREXATE HIGH DOSE |
| 330007453 | 330004261 | null | 72 | Neo-adjuvant (N) | 2016-07-19 | 2016-07-29 | Etoposide + Ifosfamide (5 days) | N | N | 330010836 | ETOPOSIDE + IFOSFAMIDE |
| 330007454 | 330004262 | 1.8 | 73 | Neo-adjuvant (N) | 2014-07-09 | 2014-07-17 | PAM x 2 post-surgery (cycles 3&4) | N | Y | 330010844 | MAP |
| 330007455 | 330008334 | 1.76 | null | Neo-adjuvant (N) | null | 2018-01-05 | Cetuximab 7 day (>Cycle 2) | N | N | 330010845 | CETUXIMAB |
| 330007456 | 330010519 | 1.62 | 60 | Curative (C) | 2013-02-11 | 2013-07-30 | OST Euramos 1 Closed Trial - M | null | null | 330010845 | METHOTREXATE HIGH DOSE |
| 330007457 | 330010519 | null | 72.7 | Curative (C) | 2016-01-07 | 2016-01-07 | CISPLATIN + FLUOROURACIL | null | Y | 330010845 | CISPLATIN + FLUOROURACIL |
| 330007458 | 330004265 | null | 53.9 | Palliative (P) | 2018-08-18 | 2018-09-18 | CISPLATIN + FLUOROURACIL | N | N | 330010880 | CISPLATIN + FLUOROURACIL |
| 330007459 | 330004265 | null | null | Palliative (P) | null | 2015-07-01 | CETUXIMAB | N | N | 330010880 | CETUXIMAB |
| 330007460 | 330004265 | 1.8 | 63 | Disease modification (D) | 2016-04-29 | 2016-05-12 | Rituximab | 02 | N | 330010880 | RITUXIMAB |
| 330007461 | 330004268 | 1.68 | 69.9 | Curative (C) | null | 2016-01-16 | OST Euramos 1 Closed Trial - M | N | N | 330010902 | METHOTREXATE HIGH DOSE |
| 330007462 | 330008337 | 1.88 | 87.3 | Palliative (P) | 2017-10-10 | 2017-10-11 | Cetuximab 7 day (>Cycle 2) | 2 | N | 330010902 | CETUXIMAB |
| 330007463 | 330012414 | 1.58 | 60 | Palliative (P) | 2017-12-11 | 2017-12-12 | CISPLATIN + FLUOROURACIL | N | N | 330010903 | CISPLATIN + FLUOROURACIL |
| 330007464 | 330012414 | 1.69 | null | Curative (C) | 2017-04-21 | 2017-04-21 | Carboplatin AUC 6 - 10 | N | Y | 330010903 | CARBOPLATIN |
| 330007465 | 330012414 | 1.8 | 63.7 | Disease modification (D) | 2016-02-13 | 2016-02-15 | Rituximab | 02 | Y | 330010903 | RITUXIMAB |
| 330007466 | 330004275 | 1.76 | 111.3 | Palliative (P) | 2018-01-03 | 2018-01-17 | Rituximab | N | N | 330010929 | RITUXIMAB |
| 330007468 | 330004280 | 1.63 | 97.9 | null | 2016-11-26 | 2016-12-27 | OST Euramos 1 Closed Trial - M | 2 | N | 330010945 | METHOTREXATE HIGH DOSE |
| 330007470 | 330004283 | 1.68 | null | Neo-adjuvant (N) | 2014-03-13 | 2014-03-13 | Etoposide + Ifosfamide (5 days) | N | N | 330010967 | ETOPOSIDE + IFOSFAMIDE |
| 330007471 | 330004284 | 1.68 | null | Neo-adjuvant (N) | 2015-10-13 | 2015-10-27 | CISPLATIN + FLUOROURACIL | N | null | 330010968 | CISPLATIN + FLUOROURACIL |
| 330007472 | 330008341 | 0 | 92 | Curative (C) | 2016-09-07 | 2016-09-10 | Etoposide + Ifosfamide (3 days) | 2 | Y | 330010974 | ETOPOSIDE + IFOSFAMIDE |
| 330007475 | 330004289 | 1.83 | 52.2 | Curative (C) | 2017-09-05 | 2017-09-11 | CISPLATIN + FLUOROURACIL | N | N | 330010979 | CISPLATIN + FLUOROURACIL |
| 330007476 | 330004291 | 1.68 | 78 | Adjuvant (A) | 2016-04-03 | 2016-05-07 | PAM x 2 post-surgery (cycles 3&4) | 2 | N | 330011005 | MAP |
| 330007477 | 330004292 | null | 63 | Curative (C) | 2013-06-05 | 2013-06-15 | Rituximab (INTRAVENOUS Maintenance) | 2 | Y | 330011010 | RITUXIMAB |
| 330007478 | 330004296 | 1.65 | null | Neo-adjuvant (N) | 2014-03-12 | 2014-07-24 | CISPLATIN + FLUOROURACIL | N | N | 330011042 | CISPLATIN + FLUOROURACIL |
| 330007479 | 330004297 | 1.77 | 104.2 | Curative (C) | 2014-12-02 | 2015-03-10 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330011043 | MAP |
| 330007482 | 330004300 | 1.81 | 68.3 | Curative (C) | 2016-05-07 | 2016-05-17 | MAP | N | N | 330011064 | MAP |
| 330007483 | 330004300 | 1.73 | 70.9 | Neo-adjuvant (N) | 2017-05-30 | 2017-05-31 | DOCETAXEL + GEMCITABINE | N | N | 330011064 | DOCETAXEL + GEMCITABINE |
| 330007484 | 330004300 | 1.7 | null | Curative (C) | 2017-09-09 | 2017-09-16 | Rituximab (Maintenance) | N | N | 330011064 | RITUXIMAB |
| 330007485 | 330004301 | 1.75 | null | Curative (C) | 2013-07-15 | 2013-07-22 | OST Euramos 1 Closed Trial - M | 2 | N | 330011097 | METHOTREXATE HIGH DOSE |
| 330007486 | 330004305 | 1.68 | 57.9 | Palliative (P) | 2016-06-02 | 2016-06-08 | Docetaxel + Gemcitabine with GCSF | 02 | N | 330011097 | DOCETAXEL + GEMCITABINE |